miRoncol Team
Victoria Xu
Co-Founder & Chief Executive Officer, miRoncol Health
- Victoria Xu is an entrepreneur and investor dedicated to advancing deep-tech innovations in biotechnology and healthcare. With a Master’s in Bioinformatics and Public Management, she leads Mironcol’s mission to provide healthy individuals a new line of defense against cancer through real-time, blood-based multi-cancer risk assessment using microRNA (miRNA) technology. Passionate about prevention and sustainability, she champions responsible innovation that improves quality of life and planetary health.
Hai Hu, PhD
Co-Founder & Chief Scientific Officer, miRoncol Health
- Dr. Hai Hu is an award-winning bioinformatics scientist specializing in cancer research and molecular diagnostics. Holding a PhD in Biophysics, he has pioneered the development of blood-based microRNA (miRNA) models for multi-cancer early detection, with results published in Scientific Reports (2024) and Cancers (2022). His work has been recognized internationally, including presentations at the World Conference on Lung Cancer and an Abstract Award at the 2024 AACR Breakthrough Meeting.
Christopher M. Gallagher, MD
Co-Founder & Chief Medical Officer, miRoncol Health
- Dr. Christopher M. Gallagher is a practicing medical oncologist with over 20 years of experience in breast cancer treatment and clinical research. A graduate of Georgetown University School of Medicine, he has led major clinical trial programs within the MedStar Health system, including roles as Co-Director of the Breast Cancer Clinical Research Program and Medical Director of Cancer Services at the Washington Cancer Institute. At Mironcol, he guides the company’s clinical strategy, ensuring scientific rigor and patient-centered application of its technology.
Gilles Erb, PhD
Medical & Scientific Director, miRoncol Health
- Dr. Gilles Erb brings over 20 years of global industry experience in oncology diagnostics and clinical validation. Holding a PhD in Medical Science, he previously served as Global Scientific Director for Integrated Molecular Medicine at Roche (FMI), where he helped advance precision oncology worldwide. At Mironcol, he leads medical and scientific strategy—transforming complex molecular insights into actionable, patient-focused solutions. His work bridges research, clinical practice, and innovation to continuously improve the accuracy, accessibility, and impact of cancer risk assessment and early detection.
